With evidences from the connectivity map and in-vitro gene expression analysis upon treatment with PI3K or RAS inhibitor, it seems possible to target PI3K or RAS in order to inhibit EXO1 modular expression in breast cancer cells. Here, EXO1 is linked to breast carcinoma.